Elevation Oncology receives FDA Fast Track designation for EO-3021 in advanced gastric cancer.

Elevation Oncology has obtained FDA Fast Track designation for EO-3021, an antibody drug conjugate targeting advanced gastric and gastroesophageal junction cancer with Claudin 18.2 expression in patients who have not responded to prior treatments. CEO Joseph Ferra highlighted the significance of this designation for accelerating development. The company aims to expand monotherapy doses and share more trial data in early 2025, with plans to start combination studies later this year.

September 23, 2024
4 Articles